BACKGROUND: B-type natriuretic peptide (BNP), heart-type fatty acid-binding protein (H-FABP), and pentraxin 3 (PTX3) each predict adverse cardiac events in chronic heart failure (CHF) patients. For prognostic evaluation from different aspects, the utility of combined measurement of the 3 biomarkers in patients with CHF was examined in the present study. METHODS AND RESULTS: Levels of BNP (associated with left ventricular dysfunction, positive if >200 pg/ml), H-FABP (marker of myocardial damage, positive if >4.1 ng/ml), and PTX3 (marker of inflammation, positive if >4.0 ng/ml) were measured in 164 consecutive CHF patients, and patients were prospectively followed with endpoints of cardiac death or rehospitalization. When patients were categorized on the basis of the number of elevated biomarkers, patients with 1, 2, and 3 elevated biomarkers had a 5.4-fold (not significant), 11.2-old (p<0.05), and 34.6-fold increase (p<0.01), respectively, in the risk of adverse cardiac events compared with those without elevated biomarkers. Kaplan-Meier analysis revealed that patients with 3 elevated biomarkers had a significantly higher cardiac event rate than patients with a lower number of elevated biomarkers. CONCLUSION: The combination of these 3 biomarkers could reliably risk-stratify CHF patients for prediction of cardiac events.
BACKGROUND:B-type natriuretic peptide (BNP), heart-type fatty acid-binding protein (H-FABP), and pentraxin 3 (PTX3) each predict adverse cardiac events in chronic heart failure (CHF) patients. For prognostic evaluation from different aspects, the utility of combined measurement of the 3 biomarkers in patients with CHF was examined in the present study. METHODS AND RESULTS: Levels of BNP (associated with left ventricular dysfunction, positive if >200 pg/ml), H-FABP (marker of myocardial damage, positive if >4.1 ng/ml), and PTX3 (marker of inflammation, positive if >4.0 ng/ml) were measured in 164 consecutive CHFpatients, and patients were prospectively followed with endpoints of cardiac death or rehospitalization. When patients were categorized on the basis of the number of elevated biomarkers, patients with 1, 2, and 3 elevated biomarkers had a 5.4-fold (not significant), 11.2-old (p<0.05), and 34.6-fold increase (p<0.01), respectively, in the risk of adverse cardiac events compared with those without elevated biomarkers. Kaplan-Meier analysis revealed that patients with 3 elevated biomarkers had a significantly higher cardiac event rate than patients with a lower number of elevated biomarkers. CONCLUSION: The combination of these 3 biomarkers could reliably risk-stratify CHFpatients for prediction of cardiac events.
Authors: Michael Böhm; Adriaan A Voors; Jean-Marie Ketelslegers; Stephan H Schirmer; Eva Turgonyi; Peter Bramlage; Faiez Zannad Journal: Clin Res Cardiol Date: 2011-07-16 Impact factor: 5.460
Authors: Nicolas Castaño; Seth C Cordts; Kari C Nadeau; Mindy Tsai; Stephen J Galli; Sindy K Y Tang Journal: Biomicrofluidics Date: 2020-04-03 Impact factor: 2.800
Authors: Wilfried Dinh; Werner Nickl; Reiner Füth; Mark Lankisch; Georg Hess; Dietmar Zdunek; Thomas Scheffold; Michael Coll Barroso; Klaus Tiroch; Dan Ziegler; Melchior Seyfarth Journal: BMC Cardiovasc Disord Date: 2011-07-05 Impact factor: 2.298